Median three-year survival with single-agent dinutuximab beta.
Kaplan–Meier estimates for progression-free survival (In total, 35 patients were evaluable for the pharmacokinetic analysis—one patient was excluded due to missing samples, and two developed HACAs during cycle 1. The concentration-time curve for dinutuximab beta administered as long-term infusion (Fig. 